Affiliations 

  • 1 Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh; Mushroom Research Centre, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia
  • 2 Department of Chemistry, Jahangirnagar University, Savar, Dhaka 1342, People's Republic of Bangladesh; Operational Integrity, SGS Bangladesh Limited, Dhaka 1205, People's Republic of Bangladesh
  • 3 Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka 1342, People's Republic of Bangladesh
  • 4 Mushroom Development Institute, Department of Agricultural Extension, Ministry of Agriculture, Government of the People's Republic of Bangladesh, Dhaka, People's Republic of Bangladesh
Int J Med Mushrooms, 2021;23(5):1-11.
PMID: 34347990 DOI: 10.1615/IntJMedMushrooms.2021038285

Abstract

Since December 2019, a de novo pattern of pneumonia, later named coronavirus disease 2019 (COVID-19), has caused grave upset throughout the global population. COVID-19 is associated with several comorbidities; thus, preventive and therapeutic strategies targeting those comorbidities along with the causative agent, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), seem imperative. In this state-of-the-art review, edible and medicinal mushrooms are featured in the treatment of SARS-CoV-2, COVID-19 pathomanifestations, and comorbid issues. Because this is not an original research article, we admit our shortcomings in inferences. Yet we are hopeful that mushroom-based therapeutic approaches can be used to achieve a COVID-free world. Among various mushroom species, reishi or lingzhi (Ganoderma lucidum) seem most suitable as anti-COVID agents for the global population.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.